270 results on '"Blatt, Lawrence M."'
Search Results
2. Mechanism of action of hepatitis B virus S antigen transport-inhibiting oligonucleotide polymer, STOPS, molecules
3. Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH.
4. Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models
5. 1381 Discovery of ALG-093989, a highly potent and orally bioavailable small molecule PD-L1 inhibitor for the treatment of cancers
6. 1382 Discovery of ALG-094103, a liver-targeted and orally bioavailable small molecule PD-L1 inhibitor for the treatment of liver cancer
7. Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles
8. Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation.
9. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
10. The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitorin vitroand confer resistance to nirmatrelvir
11. Epidemiology of chronic hepatitis viruses: hepatitis B virus and hepatitis C virus
12. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
13. A Dual Anti-Tumor Effect of a Combination of Interferon-α and 5-Flurouracil or 2-Chlorodeoxyadenosine on Natural Killer (NK) Cell Mediated Cytotoxicity
14. ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model
15. Prophylactic and therapeutic intervention of Punta Toro virus ( Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1
16. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development
17. ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibitsin vivoefficacy in a Syrian Hamster model
18. Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model
19. Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH)
20. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry
21. Development of a hyperglycosylated interferon ALFACON1: Towards monthly dosing for antiviral therapies in diseases such as chronic hepatitis C: 257
22. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study
23. Preclinical Characterization of ALS-2200, a Potent Nucleotide Polymerase Inhibitor for the Treatment of Chronic Hepatitis C: 1882
24. Analysis of ALS-2200, a Novel Potent Nucleotide Analog, Combination Drug Interactions in the Hepatitis C Virus (HCV) Subgenomic Replicon System: 1887
25. ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity over 7 days in treatment-naïve genotype 1 (GT1) patients: 86
26. Relationship of Smoking and Fibrosis in Patients With Chronic Hepatitis C
27. Abstract 4520: Preclinical characterization of ALG-031048, a novel STING agonist with potent anti-tumor activity in mice
28. Do guidelines preclude hepatitis B patients from receiving treatment?#
29. Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models
30. Des-γ-carboxyprothrombin, α-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma
31. PL-24 A review of treatment of chronic Hepatitis B and C with interferons: Challenges, triumphs and opportunities
32. 72 Pirfenidone blunts induction of bleomycin induced genes associated with idiopathic pulmonary fibrosis in mice
33. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers
34. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis
35. PIRFENIDONE ATTENUATES TRANSFORMING GROWTH FACTOR-BETA-INDUCED ACTIVATION OF P38-ALPHA AND P38-GAMMA MITOGEN–ACTIVATED PROTEIN KINASES IN HUMAN LUNG FIBROBLASTS: IMPLICATIONS FOR TREATMENT OF FIBROTIC LUNG DISEASES
36. THE COMBINATION OF INTERFERON GAMMA-1B AND PIRFENIDONE INHIBITS TRANSFORMING GROWTH FACTOR–BETA-INDUCED GENE INDUCTION IN CELLULAR MODELS OF LUNG FIBROSIS
37. Treatment of Acute Arenaviral Disease with Consensus Interferon-Alpha: 37
38. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C
39. INTERFERON GAMMA-1B INHIBITS INTERLEUKIN-4, ENDOTHELIN-1, AND TRANSFORMING GROWTH FACTOR-BETA–-INDUCED UP-REGULATION OF TYPE I COLLAGEN IN CELLULAR MODELS OF LUNG FIBROSIS
40. PIRFENIDONE MEDIATES DIFFERENTIAL EFFECTS ON LIPOPOLYSACCHARIDE-INDUCED CYTOKINE EXPRESSION IN HUMAN PERIPHERAL MONONUCLEAR CELLS
41. Treatment of Acute Arenaviral Disease with Consensus Interferon-Alpha: 37
42. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients
43. Modeling hamsters for evaluating West Nile virus therapies
44. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C
45. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America
46. Pharmacokinetics and Tolerability of an Antiangiogenic Ribozyme (ANGIOZYME™) in Healthy Volunteers
47. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics
48. Short‐Duration AL‐335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis
49. Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans
50. Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.